Showing results (391-400 of 432) with videos related to
Sort By:
Pageof 44
Rheumatology (Oxford, England)|September 10, 2015
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective studyArsène Mekinian, Eric Grignano, Thorsten Braun, et al.Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life ExperienceVincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.Pageof 44